The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for hereditary pancreatic diseases (EUROPAC-PLUS).

Abstract excerpt

INTRODUCTION AND AIMS: Surveillance is recommended for High-Risk Individuals (HRI) who are predisposed to pancreatic ductal adenocarcinoma (PDAC), because of familial (i.e., genetic) predisposition. All individuals under consideration for such surveillance in the UK, are registered and risk scored by the European Registry for Hereditary Pancreatic Diseases (EUROPAC). We generated a family risk score (FR) to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenocarcinoma
• Share to Carcinoma, Pancreatic Ductal